Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016', provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics. The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8) - The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects - The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview 7 Therapeutics Development 8 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Stage of Development 8 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Therapy Area 9 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Indication 10 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Products under Development by Companies 13 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Companies Involved in Therapeutics Development 21 Acceleron Pharma, Inc. 21 Atara Biotherapeutics, Inc. 22 Bristol-Myers Squibb Company 23 Eli Lilly and Company 24 Milo Biotechnology LLC 25 Pfizer Inc. 26 Regeneron Pharmaceuticals, Inc. 27 Sarepta Therapeutics, Inc. 28 Scholar Rock, Inc. 29 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Drug Profiles 30 AAV1-Foliistatin - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AAV9-Follistatin - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 ACE-083 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 ACE-2494 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ACE-2798 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 ATA-842 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 BMS-986089 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 domagrozumab - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 landogrozumab - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 luspatercept - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 OSX-200 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 SRK-015 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 trevogrumab - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Dormant Projects 52 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Discontinued Products 53 Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Featured News & Press Releases 54 May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association 54 May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients 55 Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes 55 Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 56 Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting 57 Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting 57 Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event 58 Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society 59 Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society 60 Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program 60 Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association 61 Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association 62 May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association 63 May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia 63 May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Acceleron Pharma, Inc., H1 2016 21 Pipeline by Atara Biotherapeutics, Inc., H1 2016 22 Pipeline by Bristol-Myers Squibb Company, H1 2016 23 Pipeline by Eli Lilly and Company, H1 2016 24 Pipeline by Milo Biotechnology LLC, H1 2016 25 Pipeline by Pfizer Inc., H1 2016 26 Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 27 Pipeline by Sarepta Therapeutics, Inc., H1 2016 28 Pipeline by Scholar Rock, Inc., H1 2016 29 Dormant Projects, H1 2016 52 Discontinued Products, H1 2016 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
